Research programme: Hedgehog cell-signalling pathway stimulants - MAX BioPharma

Drug Profile

Research programme: Hedgehog cell-signalling pathway stimulants - MAX BioPharma

Alternative Names: Hedgehog signalling pathway activators - MAX BioPharma; Oxy-133; Small molecule oxysterols - MAX BioPharma

Latest Information Update: 01 Jul 2014

Price : $50

At a glance

  • Originator MAX BioPharma
  • Class Small molecules; Sterols
  • Mechanism of Action Hedgehog cell signalling pathway stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-union fracture
  • Research Osteoporosis

Most Recent Events

  • 17 Jun 2014 MAX BioPharma receives second SBIR grant from the National Institutes of Health for the development of new oxysterol drug candidates in Osteoporosis
  • 07 Oct 2013 Early research in Osteoporosis in USA (unspecified route)
  • 07 Oct 2013 Preclinical trials in Non-union fracture in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top